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Abstract. Coronary heart disease (CHD) is caused by obstruction 
of coronary blood flow due to endothelial dysfunction triggered by 
various genetic and non-genetic risk factors such as hyperlipidemia, 
hypertension, hyperglycemia and obesity. Endothelial cell activation 
due to hyperglycaemia in diabetes mellitus induces production of 
pro-inflammatory factors that damage the cell membrane triggering 
the formation of membrane particles called microparticles. Endothe-
lial microparticles contain proteins including endothelial nitric oxide 
synthase (eNOS) which plays a role in the production of nitric oxide 
(NO). To determine the role of microparticles in the occurrence of coro-
nary heart disease in diabetes mellitus due to endothelial dysfunction, 
a study was conducted by comparing the levels of eNOS and NO in 
DM patients who had CHD with DM patients who had no CHD. Blood 
samples from 20 DM patients who had CHD and 20 DM patients who 
had no CHD of the outpatients in Cardiology Department and Inter-
nal Medicine department of regional public hospital were included in 
this study. All patients were fulfilled inclusion and exclusion criteria 
and diagnosed by the appropriate specialist. The eNOS and NO lev-
els were measured using the ELISA method. The results of this study 
show that eNOS levels in the group of DM patients who had CHD 
(21,292±12,415 ng/ml) were significantly lower (p <0.05) than those 
in the group of DM patients who had no CHD (29,721±11,952 ng/ml). 
Nitric oxide levels in DM patients who had CHD (0,053±0,021 nmol/
µl) were not statistically different to the levels in DM patients who 
had no CHD (0,047±0,032 nmol/µl). From the results of this study we 
concluded that endothelial microparticle protein eNOS plays a role in 
the occurrence of CHD due to the complications of diabetes mellitus. 
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INTRODUCTION
Coronary heart disease (CHD) is the ma-
jor cause of death in the world with mortality 
rate reaching 12.8% in the past two decades, 
especially in developed countries (Lopez et 
al., 2006). According to World Health organ-
ization (WHO) this disease is not only about 
people in developed countries, but its preva-
lence is seen to increase in developing coun-
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tries and third world countries (WHO, 2008). 
Deaths from CHD in Indonesia has reached 
5.1% and more than 30,000 patients are treat-
ed each year (Hasnawati et al., 2009).
Coronary heart disease is generally an 
obstruction in the coronary arteries due to 
atheroma plaques. The build-up of plaque 
narrows the coronary arteries and decreases 
blood flow to the heart which leads to signs 
and symptoms of coronary artery disease. The 
inflammatory process plays an important role 
starting from endothelial dysfunction that ini-
tiates atheroma plaque formation to the onset 
of plaque instability that results in acute myo-
cardial infarction. The degree of inflammation 
is a critical component in assessing plaque 
stability and progression of atherosclerosis 
(Hansson, 2005; Packard & Libby, 2008; Say-
ols-Baixeras et al., 2014).
Cardiovascular risk factors are consid-
ered to play an important role in endothelial 
dysfunction, especially hypertension, hyper-
lipidemia and hyperglycemia. Hyperglycemia 
(High blood sugar) affects people who have 
diabetes mellitus (DM) (Calles-Escandon & 
Cipolla, 2001; Funk et al., 2014). Hypergly-
cemia and diabetes mellitus cause injury to 
the vascular system by directly damaging en-
dothelial function and structure. Although the 
molecular mechanism is not fully understood, 
several hypotheses have been tested exten-
sively including increased glucose flow in 
the polyol pathway, increased production of 
advanced intracellular glycation end products 
(AGEs) and expression of AGEs receptors, 
activation of protein kinase C (PKC) and over 
activation of the hexosamine pathway. All of 
these mechanisms occur as a result of oxida-
tive stress. In studies with experimental ani-
mals Hyperglycemia was associated with the 
formation of an initial fat streak. Hypergly-
cemia increases pro-inflammatory cytokines 
such as IL-6 which generates c-reactive pro-
tein (CRP) which causes chronic inflamma-
tion and reduces bioavailability of nitric ox-
ide (NO) (Esper et al., 2006; Deanfield et al., 
2007; Van de Oever et al., 2010).
Vascular endothelial cells play an im-
portant role in vascular homeostasis because 
they regulate coagulation factors, antiplatelet 
and fibrinolytic processes of vascular cells, 
in other words they regulate the intravascular 
blood clotting process. Anti-thrombosis, an-
ti-inflammatory and anti-proliferation of the 
endothelium are regulated by NO, S-nitrosyl 
(S-NO), the signal between pericytes cell and 
endothelium and the shear stress signal to the 
glycocalyx on the endothelial surface (Pack-
ard & Libby, 2008; Libby, 2012). Pro-inflam-
matory factors attracts the pericytes toward 
the endothelial cells. The interaction between 
endothelium and pericytes cells induces this 
cells to produce proteases which damage the 
basement membrane, generating apoptosis or 
necrosis of endothelial cells or a detached of 
endothelial cells from the basement membrane 
(Vidigal et al., 2012; Schiro et al., 2014).
The constitutive calcium-calmodu-
lin-dependent enzyme nitric oxide synthase 
(NOS) will synthesize NO from the amino 
acid L-arginine in endothelial cells. Nitric ox-
ide has a various of biological properties in-
cluding maintaining vascular homeostasis and 
protecting vessels from injury. In different 
clinical disorders generating the inflammatory 
response, the main source of plasma NO is as-
sociated with activated eNOS and iNOS. Re-
ducing the release of nitric oxide to the arterial 
wall either because of excessive oxidative syn-
thesis or degradation causing atherosclerosis 
associated with various risk factors. The de-
crease of NO production in pathological con-
ditions causes serious problems in endothelial 
equilibrium (Förstermann & Münzel, 2006; 
Tripathi et al., 2007; Matheus et al., 2013).
Microparticles (MP) were first discov-
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ered as a fragment of platelets (thrombo-
cytes), termed as ‘platelet dust’ and were re-
leased by activated and apoptotic cells. Other 
than platelets, microparticles can be actively 
induced from endothelium, vascular smooth 
muscle cells, leukocytes, erythrocyte lympho-
cytes and hepatocytes. Microparticles play an 
important role in physiological and patholog-
ical processes such as inflammatory process-
es, coagulation and endothelial dysfunction 
(Agouni et al., 2008; Lovren & Verma, 2013).
The microparticle membrane consists 
mainly of lipids and proteins and the compo-
sition and size of a microparticle depends on 
the origin of the cell and the process that gen-
erates its formation (Agouni et al., 2008). En-
dothelial microparticles are formed by vesic-
ulation of endothelial plasma membranes and 
created by disruption of the stability of mem-
brane structures containing actin, vinculin 
and talin. The mechanism of endothelial dys-
function by microparticle is due to a lack of 
production of NO and causes vascular inflam-
mation that generates a pro-thrombotic state 
of atherosclerosis. Endothelial microparticles 
contain endothelial proteins such as eNOS, 
cadherin, adhesion molecules and vascular en-
dothelial growth factor receptor (VEGF-R2) 
(Tramontano et al., 2010; Dignat-George & 
Boulanger, 2011; Owens & Mackman, 2011)
The purpose of this study was to de-
termine the role of endothelial microparticle 
proteins eNOS and NO in the occurrence of 
coronary heart disease due to complication 
of diabetes mellitus as a risk factor for CHD. 
The benefit of this study is to inform that high 
blood sugar levels or hyperglycaemia in di-
abetes mellitus will trigger endothelial dam-
age that can cause CHD. This is related to the 
formation of free radicals. High blood sugar 
in diabetes mellitus is harmful to the arteries, 
and are at a much higher risk of coronary heart 
disease. The condition tends to run in families, 
but it can be controlled by prevent blood sugar 
from rising such as maintain healthy lifestyle.
MATERIALS AND METHODS
This cross-sectional study was conduct-
ed on 40 subjects divided in two groups, the 
first group is composed of 20 DM patients 
who had CHD and the second group include 
20 DM patients who had no CHD. They were 
outpatients in Cardiology Department and 
Internal Medicine Department of regional 
public hospital. Diabetes mellitus and CHD 
patients of this study were diagnosed by ap-
propriate specialist, based on clinical, elec-
trocardiogram and laboratory finding. For all 
subjects who fulfill the inclusion and exclu-
sion criteria, characteristics data such as age, 
sex, socio-economic and other CHD risk fac-
tors were recorded. The collected peripheral 
blood samples from cubital veins of patients 
were subjected to measure eNOS and NO 
levels using monoclonal antibody for ELISA 
methods following the manufacturer’s proto-
col, carried out in the Biomedical laboratory 
of the Medical Faculty of Universitas Anda-
las. All subjects gave written informed con-
sent and the procedures were approved by 
the Research Ethics Committee of Faculty of 
Medicine Universitas Andalas.
Data are expressed as means ± standard 
deviation. Statistical analysis was performed 
by one-way analysis of variance (ANOVA) 
with the Bonferroni post hoc test were used 
to evaluate the significance of differences in 
the mean values between different samples. 
The Student t test is used parametric data to 
compare the means of quantitative variables 
between two groups. Patient characteris-
tics were analyzed using nonparametric the 
Mann–Whitney U test. Statistical significance 
was assumed at P < 0.05.
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RESULTS AND DISCUSSION
Among the 40 DM patients studied, 20 
patients had CHD and the remaining 20 had 
no CHD. The characteristic of patients includ-
ed in the study obtained from anamnesis and 
laboratory finding (Table 1). There were the 
risk factors that cannot be changed such as 
age, gender and family history, and the risk 
factors that can be changed such as blood sug-
ar levels, hypertension and body weight. The 
ages of DM patients had CHD and DM pa-
tients had no CHD were in the range of 35-55 
and 32-55 years old and there were not sig-
nificantly different, as well as in gender dif-
ferences (p>0.05). Smoking, overweight and 
obesity were not different (p>0.05) between 
DM patients had CHD and DM patients had 
no CHD. There were also a similar numbers 
of patients with other risk factors such as hy-
pertension and obesity. In both groups there 
were patients who also had other risk factors 
that can be changed such as hypertension and 
hyperlipidemia. Coronary heart disease fami-
ly history of the DM patients who had CHD 
seems tend to be higher than in the DM pa-
tients who had no CHD, although there were 
not significantly different (p>0.05). The devel-
opment of atherosclerotic CHD is gradually 
increases and spread across all ethnicities and 
regions worldwide. This is related to several 
risk factors such as smoking habits, abnormal 
blood lipid levels, overweight and obesity, di-
abetes mellitus and high blood pressure (Ali 
et al., 2010). From these risk factors, diabetes 
is a risk factor that has a typical relationship 
with CHD, in which diabetic patients have 
a two to four-fold higher risk of developing 
heart disease than people without diabetes. 
Besides that CHD accounts for 65-75% of 
deaths in people with diabetes (Aronson & 
Edelman 2014). Diabetes mellitus and CHD 
are closely associated and generally coexist in 
a complex medical status (Ali et al., 2010).
Table 1. Characteristics of subjects based on the coronary heart disease (CHD) risk factors in diabetes mellitus (DM) 
patients who had CHD and DM patients who had no CHD
No Risk Factors
DM had CHD
(n=20)
DM had no CHD
(n=20)
p
1 Age 34-55 th 32-55 th
2 Gender Male 14 11 >0.05
Female 8 9
3 Smoking Smoking 11 13
No smoking 9 7
4 CHD family history Father 5 2
Mother 3 1
Father and Mother 1 1
No CHD family history 11 15
5 DM DM 17 18
DM+other risk factors 3 2
6 IMT 20 - <25 11 12
25 - < 30 6 7
> 30 3 1
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Hyperglycemia induces activation of 
the vascular endothelium that cause endothe-
lial dysfunction, characterized by reduced 
nitric-oxide (NO)-dependent phenomena 
such as vasodilation and angiogenesis. The 
long-term effects of diabetes mellitus include 
cellular injury, inflammation and various or-
gan failure complications, where one of the 
complications of diabetes is heart artery dis-
ease associated with endothelial dysfunction 
(Avogaro et al., 2011).
Energy deficiency, oxidative stress and 
the final product of the glycation process that 
occurs during the process of endothelial dys-
function can cause cell damage and apoptosis 
so that microparticles are formed. Circulating 
microparticles were increase in patients with 
metabolic syndrome. In vivo research by in-
jecting microparticles from these patients into 
experimental animals caused a disturbance of 
vascular relaxation that was dependent on the 
endothelium of the aorta and decreased eNOS 
expression due to an increase in reactive ox-
ygen species (ROS) (Martinez et al., 2005).
The eNOS level in the DM patients had 
CHD was 21.292 ± 12.415 ng / mL, lower than 
the DM patients who had no CHD (29.721 ± 
11.952 ng / mL) with significant differences 
statistically (p <0.05) (Table 2). Endothelial 
dysfunction is the initial occurrence of athero-
genesis and involves microcirculation, where-
in the inflammatory response associated with 
the formation of atherosclerotic plaques that 
causes CHD, can produce NO-induced en-
zymes (iNOS).
Endothelial nitric oxide synthase and 
NO as a product, play an important role in 
the control of vascular homeostasis. Most of 
the microparticles in the circulation originate 
from platelets and endothelial cells, both of 
which express eNOS, so it can be assumed that 
endothelium is an eNOS storage (Mahmoud 
et al., 2017). In this study eNOS levels in the 
diabetic patients who had CHD were lower 
than in the DM who had no CHD. Decreasing 
of eNOS protein expression and NO release 
causes disruption of blood vessel walls, circu-
lating cells that express this enzyme, includ-
ing platelets, endothelial progenitor cells and 
microparticles.
Based on the central role of endothelial 
cells and eNOS in controlling vascular ho-
meostasis, it is thought that eNOS activity of 
microparticles is through a role in maintain-
ing this equilibrium, and is associated with 
the production and bioavailability of NO. 
Endothelial NOS is a homeostatic regulator 
that is important in a variety of cardiovascu-
lar functions by stimulating soluble guanylyl 
cyclase and increasing cyclic GMP in smooth 
muscle cells thereby causing vasodilation of 
blood vessels. In patients with cardiovascular 
disease, disorders of vascular vasodilation are 
associated with decreased eNOS expression 
and activity in microparticles (Horn et al., 
2013).
Study conducted by Helbing et al. 
(2014) showed that high glucose exposure on 
glomerular endothelial cells increased the ex-
pression of eNOS protein, but reduced release 
of NO. The reduction in NO bioavailability 
seems to be related to excess superoxide pro-
duction and L-arginine deficiency. All of these 
changes can contribute to a decrease in plas-
ma NO concentration in patients with essen-
tial hypertension. Decreasing of NO synthesis 
can also caused by abnormal processing of 
intracellular calcium and consequently a de-
crease in NOS activity (Helbing et al., 2014). 
But whether endothelial NO production dys-
function is the cause, or the results of ather-
osclerotic lesion formation are still debated. 
Most of the evidence supports the hypothesis 
that the release of NO constitutive endotheli-
um protects against atherogenesis by prevent-
ing the proliferation of smooth muscle cells 
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and leukocyte adhesion. Insulin that has been 
linked to type II diabetes enhances the PI3K/
AKT pathway. The pathway is highly regulat-
ed by multiple mechanisms, often involving 
cross-talk with other signaling pathways. Shi 
et al. (2013) studied that the specific inhibitor 
of PI3K not only significantly downregulated 
the expression of phosphorylated Akt, but also 
downregulated the phosphorylation of eNOS. 
This suggested that the PI3K-Akt signal path-
way might participate in modulating the ac-
tivity of eNOS. The limitation of this study is 
that there was no measurement of P13K-Akt 
activity.
Table 2. Average of eNOS levels (ng / ml) in the DM patients who had CHD and the DM patients who had no CHD
No Groups n Mean±SD p
1 DM had CHD 20 21.292±12.415 < 0.05
2 DM had no CHD 20 29.721±11.952
The NO levels in the DM patients who 
had CHD were 0.053 ± 0.021 nmol / µl and in 
the DM patients who had no CHD group were 
0.047 ± 0.032 nmol / µl (Table 3). With the 
normality test, NO levels were not normally 
distributed, and after data transformation and 
continued with non-parametric tests using 
Mann-Whitney Test, there were no differenc-
es in NO levels in DM patients who had CHD 
with DM patients who had no CHD (p>0.05). 
Some studies report an increase in NO levels 
in diabetic patients, while other studies re-
port otherwise. Vapaatalo & Mervaala (2001) 
showed that there was a decrease in NO bio-
availability in diabetics patients caused by an 
increase in oxidative stress. In addition, stud-
ies conducted on obese and DM animal model, 
have a decrease in bioavailability of NO (As-
sman et al., 2016). Hyperglycemia and other 
metabolic changes can reduce NO production. 
Hyperglycemia in diabetes stimulates the pro-
duction of AGEs and protein kinase C (PKC) 
which can cause oxidative stress, producing 
ROS production, forming peroxynitrite ani-
ons as oxidants which are toxic and cause tis-
sue injury. Injury to endothelial tissue triggers 
inflammation and formation of MP. It is likely 
that if frequently repeated this hyperglyce-
mia-induced endothelial damage will have 
significant adverse clinical consequences.
Nitric oxide can have a beneficial or 
harm effect depending on its concentration. 
NO induces relaxation of blood vessels that 
reduce blood pressure, prevents platelet ag-
gregation and adhesion, smooth muscle cell 
proliferation and decreases the expression of 
pro-inflammatory genes that associated with 
atherogenesis. Nitric oxide interacts with O2ˉ 
which leads to NO inactivation and peroxyni-
trite production, which modifies post-tran-
scription protein and reduces its function. This 
stimulates the production of inflammatory 
mediators and lipid peroxidation causing an 
increase in vascular permeability resulting in 
endothelial dysfunction (Förstermann, 2010). 
Blood vessels are protected against thrombo-
sis and prevented from releasing platelet-de-
rivative growth factors that stimulate smooth 
muscle proliferation and matrix molecular 
production. Potential inhibitors of platelet 
aggregation and cells adhesion to the blood 
vessel walls are NO that released into the vas-
cular lumen. Endothelial NOS is an important 
enzyme in adaptive remodeling as a response 
to chronic vascular disorders.
Study about relationship between hy-
perglycemia and NO in diabetes mellitus 
have shown that individuals with metabol-
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ic syndrome have increased numbers of mi-
croparticles compared to healthy people and 
microparticles are associated with endothelial 
dysfunction, due to decreased eNOS expres-
sion and increased release of ROS (Adela et 
al., 2005).
Table 3. Average of NO levels (nmol/µl) in the diabetes mellitus (DM) patients who had coronary heart disease (CHD) 
and the DM patients who had no CHD
No Group n Mean±SD p
1 DM patients had CHD 20 0.053±0.021 > 0.05
2 DM patients had no CHD 20 0.047±0.032
From this study we concluded that eNOS 
and NO which are endothelial microparticles 
proteins play a role in the occurrence of coro-
nary heart disease. It could be associated with 
the biological properties of eNOS and NO 
that maintain vascular homeostasis to pro-
tect endothelium from hyperglycaemia due 
to complication of diabetes mellitus as a risk 
factor for coronary heart disease.
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